A new drug combo for AML and high-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You must have newly diagnosed AML or MDS with at least 10% blasts in the bone marrow.
- You must be in good enough health to have an ECOG performance status of 0 or 1 (able to do daily activities).
- You must not have certain genetic types of AML, like FLT3 ITD or core binding factor mutations.
- You must be willing to undergo a stem cell transplant if needed.
- You must be able to take pills by mouth or through a feeding tube.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) at lower doses plus a targeted drug called venetoclax for adults newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this reduced-intensity treatment is effective with fewer side effects.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.